// App-Quantinova.ai

e13025 : Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Researchers

Presenter

  • Stephen R. D. Johnston

Principal Investigators

  • Timothy J. Pluard

  • Judy S. Wang

  • Erika P. Hamilton

  • Dejan Juric

  • Catherine Rose Scholz

  • Elizabeth Hnitecki

  • Lei Gao

  • Lisa Cantagallo

  • Manav Korpal

  • Benoit Destenaves

  • Jianjun Alan Xiao

  • Zhaojie Zhang

  • J. Marc Marc Pipas

  • Lihua Yu

  • Tarek Sahmoud

  • Antonio Gualberto

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • St Luke's Cancer Institute, Kansas City, MO

  • The Johns Hopkins Medical Institutions, Baltimore, MD

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Kura Oncology, Cambridge, MA

  • H Biomedicine, Inc, Cambridge, MA.

  • KEW Group, Inc., Cambridge, MA

  • Merrimack Pharmaceuticals, Cambridge, MA

  • H Biomedicine, Inc, Cambridge, MA.

Locations

  • United Kingdom

  • United States

Companies

  • H3 Biomedicine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Palbociclib

  • H3B-6545

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT04288089

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved